| 标题 |
Very first experience with 68Ga/177Lu-NYM096 in patients with metastatic clear cell renal cell carcinoma
|
| 备注 |
Pubmed搜不到，doi没找到，文章期刊为Journal of Nuclear Medicine， https://jnm.snmjournals.org/content/66/supplement_1/251260
💡 该求助存在备注，如果存在信息冲突，请以备注为准
|
| 网址 |
求助人暂未提供
|
| DOI |
暂未提供，该求助的时间将会延长，查看原因？
|
| 其它 |
Wenjia Zhu, Li Huo, Meixi Liu, Xinchun Yan, Xiaoyuan Li, Guoyang Zheng and Yushi Zhang Journal of Nuclear Medicine June 2025, 66 (supplement 1) 251260; Introduction: NYM096 is a new-generation carbonic anhydrase 9 (CA9) targeting small molecule that can be labeled with both 68Ga and 177Lu. It has a higher affinity (almost 100-fold) for CA9 compared to NYM005. In this study, we aim to evaluate the safety, tolerability, and imaging characteristics of 68Ga-NYM096 and the safety, dosimetry, and recommended phase 2 dose of 177Lu-NYM096 in patients with metastatic clear cell renal cell carcinoma (ccRCC). |
| 求助人 | |
| 下载 | 暂无链接，等待应助者上传 |
PDF的下载单位、IP信息已删除
(2025-6-4)
null
Maestro_S
无极微光
秋风
suhai
彭于彦祖
aaaa
嘻嘻哈哈
Criminology34
cdercder
v0id
04d
吃葡萄不吐葡萄皮
蓝天
热心市民小红花
anz1
风吹麦浪
牧青
qiqiflower
Nole
皖公网安备34019202002308
